Workflow
Novartis(NVS)
icon
Search documents
Exploring Analyst Estimates for Novartis (NVS) Q1 Earnings, Beyond Revenue and EPS
Zacks Investment Research· 2024-04-18 14:21
Analysts on Wall Street project that Novartis (NVS) will announce quarterly earnings of $1.73 per share in its forthcoming report, representing an increase of 1.2% year over year. Revenues are projected to reach $11.5 billion, declining 11.2% from the same quarter last year.The consensus EPS estimate for the quarter has undergone a downward revision of 1.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates du ...
Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug
Zacks Investment Research· 2024-04-16 14:11
Novartis (NVS) presented encouraging results from a pre-specified interim analysis of the phase III APPLAUSE-IgAN study of Fabhalta (iptacopan).Fabhalta, an oral, Factor B inhibitor of the alternative complement pathway, is already approved by the FDA for the treatment of adults with the rare blood disorder paroxysmal nocturnal hemoglobinuria.Novartis is looking to expand the drug’s label for the treatment of immunoglobulin A nephropathy (IgAN), a heterogeneous, progressive, rare kidney disease.APPLAUSE-IgA ...
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
Zacks Investment Research· 2024-04-12 18:56
Novartis (NVS) entered into an exclusive strategic license agreement with a clinical-stage biotechnology company, Arvinas, Inc. (ARVN) , for the worldwide development and commercialization of the latter’s pipeline candidate ARV-766.  Shares of ARVN were up on the news.The deal also includes an asset purchase agreement for the sale of Arvinas’ preclinical AR-V7 program to Novartis.Per the terms of the deal, Novartis will be responsible for the global development and commercialization of ARV-766. NVS will als ...
Novartis (NVS) to Undertake Job Cuts in Development Department
Zacks Investment Research· 2024-04-11 14:46
Novartis (NVS) is set to reduce its workforce by 680, per a report by Reuters. It will do so in its development organization, which helps bring its drugs to the market.Of the reported figure, around 440 jobs will be cut in Switzerland and up to 240 in the United States over the next two to three years.This headcount reduction is separate from the restructuring program (announced earlier), wherein Novartis will slash up to 8,000 of its total global workforce of 78,000.The article stated that the company curr ...
Novartis Layoffs 2024: What to Know About the Latest NVS Job Cuts
InvestorPlace· 2024-04-10 14:12
Novartis (NYSE:NVS) layoffs are in the news Wednesday after the healthcare company announced plans to cut jobs in the U.S. and Switzerland.Starting with its U.S. jobs, the company intends to reduce its headcount by 240 workers. Employees in its product development division will be the ones hit by these cuts.The same is true for the Novartis layoffs in Switzerland, which will affect 440 workers. Both the U.S. and Swiss layoffs are set to take place over the next two to three years.A spokesperson for Novartis ...
Novartis (NVS) Stock Sinks As Market Gains: Here's Why
Zacks Investment Research· 2024-04-05 23:06
In the latest trading session, Novartis (NVS) closed at $95.79, marking a -1.14% move from the previous day. This change lagged the S&P 500's 1.11% gain on the day. Meanwhile, the Dow gained 0.8%, and the Nasdaq, a tech-heavy index, added 1.24%.The drugmaker's stock has dropped by 3.04% in the past month, falling short of the Medical sector's loss of 2.46% and the S&P 500's gain of 0.48%.Investors will be eagerly watching for the performance of Novartis in its upcoming earnings disclosure. It is anticipated ...
Novartis To Seek Label Expansion of Prostate Cancer Treatment After Successful Study
Investopedia· 2024-04-04 20:15
Key TakeawaysNovartis on Thursday said it will seek label expansion of its prostate cancer treatment, Pluvicto, following a successful Phase 3 study.The drug maker said Pluvicto helped improve survival rates when patients received it prior to certain chemotherapies.Novartis explained that it planned to seek approval to expand Pluvicto's use in the second half of 2024.Novartis shares were up more than 2% in late trading Thursday. Shares of Novartis (NVS) climbed Thursday as the pharmaceutical firm announced ...
Novartis: Higher Guidance, Now A Buy
Seeking Alpha· 2024-04-04 04:56
jetcityimage Following the Sandoz spin-off and Alcon sale, Novartis (NYSE:NVS) (OTCPK:NVSEF) has completed a big step in its transformation into a pure-play in innovative medicines (Fig 1). Novartis Pure-play Innovative Medicines Fig 1 Post Investor Day, we decided to raise our EPS forecast to CHF 7, arriving at a valuation of CHF 101.5 per share. Here at the Lab, we had mixed feelings about the company. On the one hand, Novartis is a quality business with a solid balance sheet and a strong R&D franchise. D ...
Novartis (NVS) Declines More Than Market: Some Information for Investors
Zacks Investment Research· 2024-04-02 23:21
The most recent trading session ended with Novartis (NVS) standing at $94.41, reflecting a -1.52% shift from the previouse trading day's closing. This move lagged the S&P 500's daily loss of 0.72%. Elsewhere, the Dow saw a downswing of 1%, while the tech-heavy Nasdaq depreciated by 0.95%.Heading into today, shares of the drugmaker had lost 5.98% over the past month, lagging the Medical sector's loss of 0.03% and the S&P 500's gain of 2.16% in that time.The investment community will be paying close attention ...
1 Magnificent Dividend Stock to Buy and Hold
The Motley Fool· 2024-03-24 12:15
There are plenty of dividend stocks on the market. However, some raise their payouts irregularly, while others don't have businesses that look robust enough to support payout growth for a long time. Ideally, income-seeking investors want to avoid these situations. They prefer dividend-paying companies that can afford to raise their payouts regularly and aren't at risk of reducing or suspending their dividend programs.Let's look at one stock that can give income-seekers precisely what they want: Swiss pharma ...